We applied a new strategy for the detection of N-ras gene mutations based on LightCycler technology. We designed two sets of amplimers and internal hybridization probes representing N-ras codons 12/13 and codon 61, respectively. Genomic DNAs from 134 childhood acute lymphoblastic leukemia (ALL) patients (83 common ALL, nine pre-pre-B ALL, 19 pre-B ALL, 23 T-ALL) were amplified, followed by the analysis of the melting temperatures of the PCR products on the LightCycler. PCR products exhibiting an abnormal melting characteristic were directly sequenced. Sequence analyses unravelled nucleotide substitutions at codon 12 in 10 patients, at codon 13 in three, and at codon 61 in one case. The incidence of N-ras mutations (10%) is compatible with previous reports. The LightCycler technology facilitates the rapid analysis of other genes exhibiting hot spot mutations in human malignancies. Leukemia (2000) 14, 312-315.
Introduction
Point mutations in the different members of the ras gene family are involved in a variety of human malignancies. 1 Ras genes encode p21 proteins which are located at the inner cell membrane and bear intrinsic GTPase activity. Mutational changes at critical codons of the ras genes result in loss of GTPase activity and gain of transforming ability in vitro and in vivo. N-ras mutations are frequently observed in hematological malignancies. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The incidence of N-ras mutations is approximately 20-30% in acute myeloid leukemia (AML) as well as myelodysplastic syndromes 3, 5, 9, 11, 13 and 10% in acute lymphoblastic leukemia (ALL). 2, 4, 7, 12 The role of N-ras mutations in leukemogenesis is not fully understood. The prognostic relevance of this alteration, however, appears to be more obvious in AML 13, 14 than in ALL. 7, 12 Various methods for the detection of ras mutations have been introduced. Primarily, most investigators have applied mutation-specific oligonucleotide hybridization. [2] [3] [4] [5] 7, 8, 11, 13 Recently, a combination of polymerase chain reaction (PCR) and direct sequencing 6, 7, [9] [10] [11] has been used. Allele-specific restriction analysis (ASRA) 10 and mutation-sensitive digestion analysis (MSDA) 11 have also been used to identify N-ras mutations.
Here we describe a simple PCR strategy for the rapid detection of N-ras gene mutations based on the LightCycler (LC) technology (Roche Molecular Biochemicals, Mannheim, Germany). The LC is a microvolume fluorometer combined with a thermocycler. [15] [16] [17] In addition to amplimers, two adjacent fluorescence-labeled probes are utilized to detect the specific PCR products. The 3Ј-end of a probe spanning the mutation site to be analyzed is labeled with a donor fluorophor. A second probe located directly 3Ј of the former probe bears an acceptor fluorophor at the 5Ј-end. When these two probes bind to the amplicon in close proximity, the energy of the donor fluorophor is transferred to the acceptor fluorophor, which subsequently emits a light of longer wave length. The intensity of the light emitted by the acceptor fluorophor proportionally reflects the total amount of the PCR product. We screened 134 childhood ALL patients for N-ras mutations and characterized the 14 mutation-positive cases in less than 3 days.
Materials and methods

Patients
Bone marrow or peripheral blood samples containing more than 85% of leukemic blasts were obtained after informed consent from 134 childhood ALL patients enrolled in the Multicenter Trial ALL-BFM 90 based on the German BFM (Berlin-Frankfurt-Mü nster) Study Group. 18, 19 The immunophenotypes defined elsewhere, 18 comprised 83 common ALL, nine pre-pre-B ALL, 19 pre-B ALL and 23 T-ALL. High molecular weight DNA was prepared from the diagnostic samples by standard methods.
Amplification of N-ras sequences on the LightCycler
Since the hot spots of the N-ras mutation comprise codons 12, 13 and 61, we designed two sets of amplimers and internal hybridization probes for codons 12/13 and 61, respectively. Sequences of amplimers and hybridization probes used for this study are listed in Table 1 . Two adjacent fluorescencelabeled oligonucleotides were used as hybridization probes The PCR protocol consists of a 2 min denaturing step at 95°C, followed by 45 cycles of 10 s at 50°C, 10 s at 72°C, and 1 s at 95°C. An established AML cell line, THP-1, and DNA from an AML patient exhibiting N-ras 12 and N-ras 61 mutations, respectively, served as positive controls. 3 Buffy coat (BC) DNA obtained from healthy volunteers and water were included as negative controls in every experiment.
Melting curve analysis of the amplified N-ras fragments
After amplification, the PCR products were gradually (0.2°C/s) heated from 50°C to 95°C and at the same time the decrease
Figure 1
Schematic representation of amplimers (arrows) and two adjacent hybridization probes used for LC analysis of N-ras.
Leukemia of the fluorescent level was continuously recorded. The sudden change of fluorescence was converted to a melting peak by plotting of the negative derivative of the fluorescent signal corresponding to the temperature (−dF/dT) on the software. Nras mutations were identified through the comparison of the melting peak of each patient's N-ras locus with that of normal control DNA.
Direct sequencing
PCR products showing abnormal melting curves were electrophoresed on an agarose gel and purified with a QIAEXII Kit (Qiagen, Hilden, Germany). For direct sequencing of N-ras codons 12/13, we used an internal sequencing primer, 5Ј-GGT TTC CAA CAG GTT CTT GC-3Ј. For codon 61, the same primer as for amplification (Table 1) 
Restriction analysis
Allele-specific restriction analysis (ASRA) 10 of N-ras codon 13 and mutation-sensitive digestion analysis (MSDA) 11 of N-ras codon 12 were performed with minor modifications 12 in 53 randomly selected cases of this ALL series. Briefly, a 135 bp fragment amplified by primers which contain mismatches at codon 12 was cut with BstNI and primers containing mismatches sensitive to codon 13 were used to amplify a 100 bp fragment, which was subsequently digested with PflMI. Digested fragments were electorophoresed on a 3% agarose gel (FMC, Rockland, ME, USA).
Results and discussion
We analyzed N-ras mutations in 134 childhood ALL patients using the LightCycler (LC) technology, identified 14 patients with an abnormal melting curve, and also observed an aberrant pattern in both N-ras mutation-positive AML controls. Representative results are shown in Figure 2 . The frequency of N-ras mutations (10%) among different ALL immunophenotypes (Table 2 ) equals that of previous reports. Sequence analyses demonstrated substitutions at codon 12 in 10 patients, at codon 13 in three, and at codon 61 in one case ( Table 3 ). The most frequent substitution was GGT to GAT at codon 12. The majority of the patients harboring N-ras mutations (11/14) showed a G to A transversion, whereas two showed a G to T transition (Table 3 ). This finding is in line with the preferential mutation pattern of the N-ras gene in ALL observed by others. 4, 12 Interestingly, we also demonstrated an N-ras codon 61 mutation in patient 97 ( Figure 3 and Table  3 ). To our knowledge, N-ras 61 mutations in childhood ALL have not been reported thus far. In patient 77 the melting curve and sequence analysis only revealed the mutated N-ras 12 allele (Figures 2 and 3) . We assume that the second allele has been deleted since the alternative explanation of a homozygous mutation appears less likely.
In order to confirm the reliability of the LC analysis, we also screened 53 randomly selected cases of this ALL series for Nras codon 12 and 13 mutations by MDSA and ASRA, respectively. [10] [11] [12] The PCR products of seven patients showed an
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Figure 2
Representative results of melting curve analyses. (a) Nras codon 12/13. ALL patient 77 shows an aberrant melting temperature as compared to that of a buffy coat (BC) control. The melting curve of this patient lacks the wild-type peak. (b) N-ras codon 61. ALL sample 97 shows both a normal and an abnormal peak, indicating heterozygosity for this mutation.
Table 2
Incidence Total 134 14 (10) aberrant restriction pattern in complete agreement with the LC study (Table 3) . Mutational analysis of N-ras using the LC bears several advantages. Firstly, the rapid thermocycling of the LC enabled us to screen 134 samples in 2 days. The analysis for each codon was finished in an hour. Since up to 32 samples, including positive and negative controls, can be simultaneously analyzed per run, it is possible to screen N-ras codons 12/13 and 61 of more than 80 patients per day. In fact, LC screening plus sequence analysis was completed in this cohort of patients within 3 days. Oligonucleotide hybridization and single-strand conformation polymorphism (SSCP) analyses are laborious. Moreover, these methods often require radioisotopes. MSDA and ASRA which are based on nested PCR and restriction enzyme digestions are also timeconsuming. For mutational analysis on the LC there is no need for electrophoresis since the internal hybridization probes are specific to the target. Secondly, not only codons 12, 13 and 61 of N-ras but also adjacent sequences are screened by the LC method (Table 1 and Figure 1 ). For example, an N-ras mutation at codon 11 6 as well as a silent mutation at codon 15 which interferes with the detection of a codon 12 mutation by oligonucleotide hybridization 20 have previously been reported. Our F-12 probe could theoretically detect such mutations because this probe covers codons 9 to 15. However, no mutation outside codons 12, 13 and 61 was found in our series. Thirdly, PCR products screened on the LC can be directly sequenced although the PCR reaction contains only 20 l. In the absence of any non-specific band the specific amplification products showed intensive fragments upon gel electrophoresis. These PCR products contained sufficient amounts of DNA for consecutive cycle sequencing. However, we recommend purification of the amplified fragment by cutting out respective bands from agarose gel because the PCR reaction contains four different oligonucleotides, which may cause competition problems.
Only two sets of four primers, each with two fluorescencelabeled probes, are used to screen large series of patients for N-ras mutations. This, combined with its relatively high speed and the fact that post-PCR processing is not necessary, makes this technique very cost-effective.
In accordance with previously published studies, our results show that N-ras mutations are detectable in approximately 10% of patients with ALL. The clinical relevance of N-ras gene mutations in ALL remains controversial, partly because rather small series of patients have been analyzed thus far. 7, 12 Examination of N-ras in prospective trials comprising many more patients could determine the prognostic significance of this type of oncogene activation in ALL.
In conclusion, the method described here represents a rapid, simple and reliable technique for the identification of N-ras gene mutations which could easily be adapted to other loci with known mutational hot spots. During the review process of this manuscript two articles describing the detection of point mutations with the LC technology were published. 21, 22 
